# Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

> **NCT03867045** · NA · TERMINATED · sponsor: **Duke University** · enrollment: 1 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma Treated With Cabozantinib

## Interventions

- **DEVICE:** Usability of an electronic symptom management application

## Key facts

- **NCT ID:** NCT03867045
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-21
- **Primary completion:** 2019-12-16
- **Final completion:** 2019-12-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study deemed non-essential under COVID pandemic,
- **Last updated:** 2021-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867045, "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03867045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*